Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIVI 007 in Patients with Hypercholesterolemia on Stable Statin Therapy
NCT04164888Phase 2Completed
- Sponsor
- CiVi Biopharma
- Start
- Nov 2019
- Primary completion
- Jun 2020
- Modality
- Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of civi 007 in hypercholesterolemia (4 arms), sponsored by CiVi Biopharma. Primary endpoint: Assessment of the Pharmacodynamic Effect of CIVI 007 at Day 85. Started Nov 2019; status: completed.
02
Drugs
civi 007
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04164888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164888.